Reactions 1704, p347 - 2 Jun 2018 Ischaemic stroke and myocardial infarction: 2 case reports In an observational retrospective study of 167 patients, two patients [ages and sexes not stated] were described, of which, one developed ischaemic stroke and the second developed myocardial infarction during treatment with sorafenib for advanced hepatocellular carcinoma (HCC) [routes, durations of treatments to reactions onsets and outcomes not stated]. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed ischaemic stroke. The patient, who had advanced HCC, started receiving treatment with sorafenib 400mg twice daily. Subsequently, the patient developed myocardial infarction. Author comment: "All patients received 800 mg/day sorafenib (400 mg twice/day) as an initial dosage." "With regards to the toxicity of treatment, the primary adverse reactions registered in the medical records . . . 1 patient suffered an ischaemic stroke . . . 1 exhibited myocardial infarction". Sanchez AIP, et al. Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncology Letters 15: 8863-8870, No. 6, Jun 2018. Available from: URL: http:// doi.org/10.3892/ol.2018.8400 - Spain 803324158 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera